Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05994157 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Y-mAbs Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT05994157 is a Phase 1 study that was terminated before completion, run by Y-mAbs Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT05994157, a Phase 1 study, was terminated before completion, sponsored by Y-mAbs Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
Patients with non-Hodgkin Lymphoma will be treated with CD38-SADA:177Lu-DOTA complex (The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA) to establish optimal and safe therapeutic doses and dosing schedule of CD38-SADA, and 177Lu-DOTA.
Interventions
- DRUG CD38-SADA:177Lu-DOTA Complex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2025-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05994157
The ClinicalTrials.gov registry entry for NCT05994157 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Y-mAbs Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD38-SADA:177Lu-DOTA Complex is the first listed.
NCT05994157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05994157 about?
NCT05994157 is a clinical study titled "Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma". Patients with non-Hodgkin Lymphoma will be treated with CD38-SADA:177Lu-DOTA complex (The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA) to establish optimal and safe therapeutic doses and dosing schedule of CD38-SADA, and 177Lu-DOTA.
What is the current status of trial NCT05994157?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2025-04-21. Estimated completion is 2025-10-15.
What interventions are being tested in trial NCT05994157?
The interventions under investigation include: CD38-SADA:177Lu-DOTA Complex (DRUG).
Who is sponsoring clinical trial NCT05994157?
This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.